ASSIST Screening Test

The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) is a World Health Organization (WHO) validated screening tool that assesses substance use risk across 10 substance categories including tobacco, alcohol, cannabis, cocaine, amphetamines, inhalants, sedatives, hallucinogens, opioids, and other drugs. Each substance receives a specific substance involvement score (0-39 points) calculated from eight questions covering lifetime use, frequency in past 3 months, craving, health/social/legal/financial problems, failed control attempts, and others' concerns. The scoring thresholds determine intervention levels: 0-3 points = Low Risk (no intervention needed beyond feedback); 4-26 points = Moderate Risk (brief intervention recommended—typically a single 5-15 minute counseling session on health consequences and reduction strategies); 27+ points = High Risk (referral to specialist assessment for intensive treatment). For example, someone reporting cannabis use 2-3 times weekly (scoring 3 points), with weekly cravings (3 points), occasional failed quit attempts (3 points), and friend concerns (3 points) totals 12 points—solidly in the moderate risk category requiring brief intervention. The ASSIST demonstrates excellent sensitivity (80-97%) and specificity (85-96%) across validation studies in 12 countries, making it the gold standard for multi-substance screening in primary care, emergency departments, and criminal justice settings.

ASSIST uniquely separates lifetime use (Question 1) from recent use patterns (Questions 2-8) to distinguish experimental past use from current problematic use—this prevents misclassifying someone who tried cannabis twice in college but hasn't used in 10 years. Question 1 asks about ever using each substance and scores: never=0, yes but not in past 3 months=2, yes in past 3 months=3. If someone scores 0 or 2 on Question 1 for a substance, subsequent questions about that substance are skipped entirely. Only Question 2-8 responses contribute to intervention risk scoring, covering past 3-month frequency (0-6 points), craving (0-6 points), health/social/legal/financial problems (0-6 points), failure to do expected activities (0-6 points), concern from others (0-6 points), failed control attempts (0-6 points), and injecting behavior (0-2 points). This structure matters clinically because someone might report lifetime cocaine use (Question 1=2 points) but no recent use—their cocaine-specific score remains 2 points (low risk, no intervention). Conversely, someone with recent alcohol use 3-4 times weekly (4 points), daily cravings (6 points), weekly hangovers affecting work (4 points), and partner concerns (4 points) totals 18 points for alcohol—moderate risk requiring brief intervention despite not meeting diagnostic criteria for alcohol use disorder. This granular approach allows providers to target interventions to specific substances causing current problems rather than flagging everyone with any lifetime exposure, making ASSIST particularly valuable in settings where polysubstance use is common.

When ASSIST identifies moderate risk (4-26 points) for any substance, evidence-based brief interventions (BI) lasting 5-15 minutes can reduce substance use by 20-30% without specialist referral. The structured BI approach includes: (1) Personalized feedback—explain the specific ASSIST score and what it means (e.g., "Your cannabis score of 14 indicates moderate risk, meaning your current use pattern is likely causing some health or social problems"); (2) Health education—discuss substance-specific risks relevant to their use pattern (for someone using cannabis 2-3 times weekly, discuss cognitive impacts, respiratory effects, dependence risk of 9% with regular use); (3) Decisional balance—explore pros and cons of continued use ("What do you like about using cannabis? What concerns you?"); (4) Goal setting—help identify realistic reduction goals (e.g., from 10 drinks weekly to 6 drinks weekly over 4 weeks); (5) Action planning—identify specific strategies (avoiding triggers, substituting activities, enlisting friend support); (6) Written materials—provide take-home resources on substance effects and reduction strategies. For example, a 28-year-old with ASSIST cocaine score of 11 (used monthly in past 3 months, occasional cravings, once missed work deadline) receives BI focusing on stimulant cardiovascular risks, strategies for refusing offers at parties, and substituting exercise for the energy-seeking behavior—studies show this 10-minute intervention reduces cocaine use frequency by approximately 35% at 3-month follow-up. Brief interventions show strongest efficacy for alcohol (25-30% reduction), cannabis (20-25% reduction), and tobacco (15-20% reduction), with effect sizes diminishing but still significant for other substances. The key is intervening at moderate risk before dependence develops, when motivation for change is higher and intervention requirements are lower.

ASSIST excels as a comprehensive multi-substance screener taking 5-10 minutes to assess all 10 substance categories simultaneously, making it ideal for settings where polysubstance use prevalence is unknown (primary care, emergency departments, mental health clinics, criminal justice intake). Its major advantage is detecting unexpected problematic use—a patient presenting for depression screening might reveal prescription opioid misuse (ASSIST opioid score 15) previously unknown to providers. However, single-substance tools offer greater depth for specific contexts: AUDIT (Alcohol Use Disorders Identification Test) provides more granular alcohol assessment with 10 questions yielding 0-40 points (0-7=low risk, 8-15=hazardous, 16-19=harmful, 20+=dependent), capturing details like binge frequency and inability to stop that ASSIST's briefer alcohol questions miss. Use AUDIT when alcohol is the known primary concern—for example, a patient admitting to drinking problems should complete AUDIT rather than ASSIST to better quantify severity and guide treatment intensity. DAST-10 (Drug Abuse Screening Test) focuses exclusively on drug-related consequences (work/school problems, relationship issues, medical problems) without distinguishing specific substances, useful when any illicit drug use needs quick yes/no screening. CRAFFT is designed specifically for adolescents ages 12-21 with developmentally appropriate questions. Clinical decision framework: Use ASSIST for (1) universal screening when substance use is unknown, (2) polysubstance users requiring substance-specific risk stratification, (3) international settings (ASSIST has WHO validation in 12 languages); use AUDIT when (1) alcohol is identified primary problem, (2) more detailed quantity/frequency assessment needed for treatment planning, (3) monitoring alcohol use disorder treatment progress; use DAST when (1) rapid drug screening needed (<2 minutes), (2) collapsing all drugs into single risk score is acceptable, (3) patient shows high defensiveness (DAST's indirect consequence-based questions may elicit more honest responses). In specialized addiction treatment, ASSIST serves as initial triage while single-substance tools provide depth for primary problem substances.

Despite strong psychometric properties, ASSIST has several important limitations requiring awareness: (1) Self-report bias—patients may underreport use due to stigma, legal concerns, or fear of consequences. ASSIST sensitivity drops from 85% with honest reporting to 60-70% when patients minimize. Mitigation strategies include: establishing rapport and confidentiality before screening, using normalizing language ("Many people use substances to cope with stress—have you?"), screening all patients universally rather than selectively (reduces perception of being singled out), and conducting screening in private settings. (2) 3-month timeframe limitations—someone in early recovery (60 days sober) may score high risk based on use 70 days ago despite current abstinence. Solutions: use clinical judgment to distinguish active use from recent recovery, consider 30-day versions of ASSIST questions when appropriate, and document abstinence duration alongside scores. (3) Prescription medication ambiguity—ASSIST asks about sedative and opioid use but doesn't clearly differentiate prescribed use from misuse. A patient taking prescribed benzodiazepines as directed shouldn't score sedative risk points. Mitigation: clarify that questions address use "in a way not prescribed or for reasons other than prescribed" when asking about prescription substances. (4) Cultural and linguistic considerations—substance terminology varies across cultures ("cannabis" vs. "marijuana" vs. "weed"). Use locally appropriate terms and ensure translated versions maintain conceptual equivalence. (5) Injection drug use question sensitivity—Question 8 about injecting may deter honest responses due to stigma. Some protocols move this question to separate confidential health screening. (6) Limited sensitivity for emerging substances—ASSIST's "other drugs" category doesn't capture specifics about synthetic cannabinoids, kratom, or novel psychoactive substances gaining popularity. Clinicians should supplement with open-ended questions about substances not explicitly listed. (7) Score inflation with polysubstance use—someone using multiple substances moderately may appear higher risk than someone with severe single-substance dependence. Evaluate substance-specific scores individually rather than summing across all substances. Despite these limitations, ASSIST remains highly effective when administered with clinical sensitivity and supplemented with clinical interview.

ASSIST scores translate directly into evidence-based intervention pathways through a stepped care approach matching treatment intensity to risk level: Low Risk (0-3 points): Provide positive reinforcement and general health promotion information. No follow-up needed unless scores increase at subsequent screenings. Document baseline scores for comparison during future visits (recommended annual re-screening in primary care). Moderate Risk (4-26 points): Deliver brief intervention immediately (5-15 minutes) covering personalized feedback, health risks, and reduction strategies. Schedule follow-up in 1-3 months to re-administer substance-specific questions and assess progress—successful reduction should show 30-50% decrease in score. If scores remain elevated or increase, escalate to intensive outpatient counseling (3-9 hours weekly for 8-12 weeks). For scores 15-26 (upper moderate range), consider co-administering single-substance tools (AUDIT for alcohol, DAST for drugs) to determine if diagnostic thresholds for substance use disorder are met, potentially warranting immediate referral. High Risk (27+ points): Provide immediate referral to addiction specialist or treatment program—this score range correlates with DSM-5 moderate-to-severe substance use disorder requiring specialized care. Treatment options include: intensive outpatient programs (IOP: 9-12 hours weekly), partial hospitalization programs (PHP: 20+ hours weekly), residential treatment (24/7 care for 30-90 days), or medication-assisted treatment (MAT: buprenorphine for opioids, naltrexone for alcohol/opioids, disulfiram for alcohol). Special considerations: For cannabis scores 15+, assess for cannabis use disorder and consider referral even in moderate range given limited brief intervention efficacy for heavy cannabis use. For stimulant (cocaine/amphetamine) scores 12+, screen for cardiovascular complications and mental health comorbidities requiring integrated treatment. For opioid scores 10+, evaluate for opioid use disorder and MAT candidacy—even moderate-risk opioid use warrants specialist consultation due to overdose risk. Document specific substance scores, intervention provided, and follow-up plan in medical record. Use ASSIST scores for treatment matching—patients with single high-risk substance benefit from substance-specific treatment tracks (alcohol treatment program), while polysubstance users with multiple moderate-risk scores may need comprehensive dual diagnosis or integrated care programs addressing co-occurring mental health issues often driving multi-substance use.